NATX Plasmids, for: DNA Vaccines, Gene Therapeutics, Viral Vectors andBiophamacueticals

Research and Development
Technologies

NTC Contacts:
Phone: (402) 323-6289 (natx)
Fax: (402) 323-6292
Email: support@natx.com

site map | home | contact us
NTC PRODUCTS AND SERVICES

MAMMALIAN EXPRESSION VECTORS
X• Antibiotic-Free Vectors
X• Rig-I Activating Vectors
X• Linear Vectors
X• Recombineering Vectors
X• Gene Silencing (transient)
X• Gene Silencing (retroviral, stable)
X• Anti-Silencing Elements
X• Vector Pricing

CELL LINES
X• Autolytic E. coli Cell Lines
X• dcm- Strains

VACCINES & ADJUVANTS
X• DNA Vaccines
X• Rig-I Activating DNA Vaccines
X• Thermostable Protein Expression

PRECISION CLONING
X• Services and Pricing

RECOMBINANT PROTEINS
X• pVEX™-E. coli Expression Vectors
X• Fluorescent Proteins
X• Products, Vectors, Services, Prices
X• CofA (SAMPLE)

PLASMIDS
X• Small Scale Plasmid DNA
X• Small Scale C of A
X• Large Scale Plasmid DNA
X• Large Scale C of A
X• Plasmid DNA Order Form
X• E. coli Cell paste
X• NEW! Plasmid Detox Service
X• Additional Testing

PROCESS DEVELOPMENT

DNA FERMENTATION PROCESS
X• HyperGRO™ Publications
X• E. coli Cell Paste

HYPERTAQ™ DNA POLYMERASE

CONTRACT QC
X• E. coli Genomic DNA Testing
X• Residual RNA qPCR
X• Residual RNA gel
X• Supercoil Assay
X• Lymulus Endotoxin Testing




























Autolysis technologyX|XHyperGRO™ Fermentation process (pDNA)X|XpVEX™ Recombinant protein production (E. coli) X|XGenome Mass Transfer (GMT™) DNA Vaccination technologyX|XRetro-Vector technology



Autolysis technology

Microbial strains have been created at NTC for simplified purification of recombinant products, such as plasmid DNA and recombinant protein therapeutics. This eliminates the need for complicated chemical or physical methods of cell cracking. [Patent Ref: PCT/US05/28870; PCT/08/06553]

HyperGROtm fermentation process: Record yields for plasmid DNA production

NTC’s HyperGROtm fermentation process and media are used routinely for production of gene therapy vectors and DNA vaccines.  Improvements in fed-batch fermentation resulted in plasmid DNA yields of >2.2g/L. [Patent Ref: PCT/US05/29238]

Recombinant protein production (E. coli)

NTC’s pVEX™ system is arguably the most advanced E. coli recombinant protein production suite available in the industry today, capable of protein yields routinely in the range of 2-20g/L.

Genome Mass Transfer (GMT™) Strain engineering Technology

GMT is a disruptive NTC technology, which facilitates the transfer of desirable traits freely between strains. The strategy is to directly transfer genomic DNA from a strain with a desired property into a recipient strain that expresses recombineering genes. GMT replaces older technology, such as phage P1 transduction. For example, genomic DNA becomes efficiently integrated into the recipient host genome through homologous recombination, after transfer, for example, by electroporation. In some cases, amplified DNA is transferred directly from cell lysates, dramatically simplifying the task of genome engineering. [Patent Ref: PCT/US08/06548]

DNA Vaccination technology

DNA vaccines have been improved through the introduction of NTC’s RNA elements technology (RNAe), redirecting the innate immune response through alteration of pattern recognition elements.  NTC’s pDNAVACCUltra vectors are designed for: rapid deployment, multi-mode presentation, enhanced expression, enhanced production yield, and antibiotic-free selection. [Patent Ref: PCT/US06/02174; PCT/US08/06554]

Retro-Vector technology

Retro-vectors, derived from retroviruses, are among the most ubiquitous of reagents used for gene therapy research.  NTC’s retro-vector technologies include: Retrotransposons (US 6,4100,220; US5,879,933); Vectors for gene transfer (US6,027,722; 6,287,863); Self-assembling genes (US 6,410,220); and Viral packaging signal without gag gene sequences (US 6,573,091).